Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

The Lancet Diabetes & Endocrinology, Год журнала: 2022, Номер 10(6), С. 393 - 406

Опубликована: Апрель 22, 2022

Язык: Английский

---

Obesity, Inflammation, and Immune System in Osteoarthritis

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Июль 4, 2022

Obesity remains the most important risk factor for incidence and progression of osteoarthritis (OA). The leading cause OA was believed to be overloading joints due excess weight which in turn leads destruction articular cartilage. However, recent studies have proved otherwise, various other factors like adipose deposition, insulin resistance, especially improper coordination innate adaptive immune responses may lead initiation obesity-associated OA. It is becoming increasingly evident that multiple inflammatory cells are recruited into synovial joint serves an role pathological changes joint. Polarization macrophages macrophage-produced mediators extensively studied linked destructive synovium major such as neutrophils, eosinophils, dendritic pathogenesis has not been fully evaluated. Although system contribute obesity-induced still under exploration, a quantity literature indicates enriched population T B compared with healthy control. interplay between variety reside constitute vicious cycle, obese individuals. This review addresses obesity all involved summarised animal human trials knowledge gaps highlighted. also touches base on interventions currently clinical trials, different stages testing, their shortcomings discussed understand future direction could help understanding multifactorial aspects where inflammation significant function.

Язык: Английский

---

MAFLD: How is it different from NAFLD?

Clinical and Molecular Hepatology, Год журнала: 2022, Номер 29(Suppl), С. S17 - S31

Опубликована: Ноя. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Язык: Английский

---

The Role of Obesity in Type 2 Diabetes Mellitus—An Overview

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(3), С. 1882 - 1882

Опубликована: Фев. 4, 2024

Obesity or excessive weight gain is identified as the most important and significant risk factor in development progression of type 2 diabetes mellitus (DM) all age groups. It has reached pandemic dimensions, making treatment obesity crucial prevention management DM worldwide. Multiple clinical studies have demonstrated that moderate sustained loss can improve blood glucose levels, insulin action reduce need for diabetic medications. A combined approach diet, exercise lifestyle modifications successfully subsequently ameliorate ill effects deadly complications DM. This also helps largely prevention, control remission are chronic diseases increasing globally, requiring new approaches to manage prevent obese individuals. Therefore, it essential understand mechanistic link between two design a comprehensive increase life expectancy quality patients with obesity. literature review provides explicit information on definitions DM, incidence prevalence individuals, indispensable role pathophysiology their link. discusses outlines recent these associated conditions. Additionally, vivo discussed here they pave way more rigorous therapeutic approaches.

Язык: Английский

---

8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2024

Diabetes Care, Год журнала: 2023, Номер 47(Supplement_1), С. S145 - S157

Опубликована: Дек. 11, 2023

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Язык: Английский

---

Gut microbiota induces DNA methylation via SCFAs predisposing obesity-prone individuals to diabetes

Pharmacological Research, Год журнала: 2022, Номер 182, С. 106355 - 106355

Опубликована: Июль 14, 2022

Язык: Английский

---

Relevance of body composition in phenotyping the obesities

Reviews in Endocrine and Metabolic Disorders, Год журнала: 2023, Номер 24(5), С. 809 - 823

Опубликована: Март 17, 2023

Obesity is the most extended metabolic alteration worldwide increasing risk for development of cardiometabolic alterations such as type 2 diabetes, hypertension, and dyslipidemia. Body mass index (BMI) remains frequently used tool classifying patients with obesity, but it does not accurately reflect body adiposity. In this document we review classical new classification systems phenotyping obesities. Greater accuracy accessibility to composition techniques at same time increased knowledge use factors leading a more refined obesity. It incorporate these advances into routine clinical practice better diagnose overweight optimize treatment living

Язык: Английский

---

Obesity in adults

The Lancet, Год журнала: 2024, Номер 404(10456), С. 972 - 987

Опубликована: Авг. 16, 2024

Язык: Английский

---

Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(4), С. 2338 - 2338

Опубликована: Фев. 16, 2024

Diabetes mellitus (DM) is a highly prevalent disease worldwide, estimated to affect 1 in every 11 adults; among them, 90–95% of cases are type 2 diabetes mellitus. This partly attributed the surge prevalence obesity, which has reached epidemic proportions since 2008. In these patients, cardiovascular (CV) risk stands as primary cause morbidity and mortality, placing substantial burden on healthcare systems due potential for macrovascular microvascular complications. this context, leptin, an adipocyte-derived hormone, plays fundamental role. hormone essential regulating cellular metabolism energy balance, controlling inflammatory responses, maintaining CV system homeostasis. Thus, leptin resistance not only contributes weight gain but may also lead increased cardiac inflammation, greater fibrosis, hypertension, impairment metabolism. Understanding relationship between obese individuals with DM (T2DM) could improve management prevention complication. Therefore, narrative review, we will discuss evidence linking presence, severity, and/or prognosis obesity T2DM regarding disease, aiming shed light implications better preventive strategies.

Язык: Английский

---

Tirzepatide for Obesity Treatment and Diabetes Prevention

New England Journal of Medicine, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 13, 2024

BackgroundObesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown provide substantial sustained reductions in body weight persons with obesity over a 72-week period. Here, we report 3-year safety outcomes its efficacy reducing delaying progression diabetes both prediabetes.MethodsWe performed phase 3, double-blind, randomized, controlled trial which 2539 participants obesity, whom 1032 also had prediabetes, were assigned 1:1:1:1 ratio receive at once-weekly dose 5 mg, 10 or 15 mg placebo. The current involved who received their placebo for total 176 weeks, followed by 17-week off-treatment three key secondary end points, I error, percent change from baseline week onset during 176-week 193-week periods.ResultsAt mean among −12.3% 5-mg dose, −18.7% 10-mg −19.7% 15-mg as compared −1.3% those (P<0.001 all comparisons placebo). Fewer diagnosis groups than group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 0.1; P<0.001). After 17 weeks off treatment placebo, 2.4% 13.7% (hazard 0.12; CI, 0.1 0.2; Other coronavirus 2019, most common adverse events gastrointestinal, mild moderate severity occurred primarily dose-escalation period first 20 trial. No new signals identified.ConclusionsThree years prediabetes resulted reduction markedly lower risk that (Funded Eli Lilly; ClinicalTrials.gov number, NCT04184622.)

Язык: Английский

---